Abstract
<div>Abstract<p>The cyclin-dependent kinase (CDK) inhibitors, p18<sup>INK4c</sup> and p16<sup>INK4a</sup>, both have the credentials of tumor suppressors in human cancers and mouse models. For p16<sup>INK4a</sup>, the underlying rationale is its role in senescence, but the selective force for inactivation of p18<sup>INK4c</sup> in incipient cancer cells is less clear. Here, we show that in human fibroblasts undergoing replicative or oncogene-induced senescence, there is a marked decline in the levels of p18<sup>INK4c</sup> protein and RNA, which mirrors the accumulation of p16<sup>INK4a</sup>. Downregulation of <i>INK4c</i> is not dependent on p16<sup>INK4a</sup>, and RAS can promote the loss of <i>INK4c</i> without cell-cycle arrest. Downregulation of p18<sup>INK4c</sup> correlates with reduced expression of menin and E2F1 but is unaffected by acute cell-cycle arrest or inactivation of the retinoblastoma protein (pRb). Collectively, our data question the idea that p18<sup>INK4c</sup> acts as a backup for loss of p16<sup>INK4a</sup> and suggest that the apparent activation of p18<sup>INK4c</sup> in some settings represents delayed senescence rather than increased expression. We propose that the contrasting behavior of the two very similar INK4 proteins could reflect their respective roles in senescence versus differentiation. <i>Cancer Res; 72(1); 165–75. ©2011 AACR</i>.</p></div>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
